Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes

Clinical Lipidology

Volumn 6, Issue 5, 2011, Pages 539-547

  Rizzo, Manfredi ^a   Tomkin, Gerald H ^b   Patti, Angelo Maria ^a   Pepe, Ilenia ^a   Valerio, Maria Rosa ^a   Di Rosa, Salvatore ^c   Rini, Giovam Battista ^a   Di Fede, Gaetana ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c Azienda Ospedali Riuniti Villa Sofia Cervello   (Italy)

Author keywords

dense LDL; diabetes; LDL size; prevention; small; therapy

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; TRIACYLGLYCEROL;

ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DYSLIPIDEMIA; HUMAN; MOLECULAR SIZE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

SCOPUS;

EID: 80054875286     PISSN: 17460875     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.11.46     Document Type: Review

References (100)

1. American Diabetes Association. Management of dyslipidemia in adults with diabetes (position statement).Diabetes Care 26(Suppl. 1), S83-S86, (2003).
2. Tomkin GH. Targets for intervention in dyslipidemia in diabetes. Diabetes Care 31 (Suppl. 2), S241-S248 (2008).
3. Rizzo M, Berneis K. Low-density-lipoproteins size and cardiovascular risk assessment. QJM 99, 1-14 (2006). (Pubitemid 43124966)
4. National Cholesterol Education Program (NCEP).Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421 (2002).
5. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J. Lipid. Res. 43, 1363-1379 (2002).
6. Bjornheden T, Babyi A, Bondjers G, Wiklund O. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 123, 43-56 (1996). (Pubitemid 26175068)
7. Galeano NF, Al-Haideri M, Keyserman F, Rumsey SC, Deckelbaum RJ. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J. Lipid. Res. 39, 1263-1273 (1998). (Pubitemid 28270090)
8. Camejo G, Lopez A, Lopez F, Quinones J. Interaction of low density lipoproteins with arterial proteoglycans. The role of charge and sialic acid content. Atherosclerosis 55, 93-105 (1985). (Pubitemid 15064942)
9. Tribble DL, Rizzo M, Chait A, Lewis DM, Blanche PJ, Krauss RM. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am. J. Med. 110, 103-110 (2001). (Pubitemid 32126429)
10. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 93, 189-199 (1992).
11. de Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, Stalenhoef AF. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler. Thromb. 11, 298-306 (1991).
12. Owens D, Maher V, Collins P, Johnson A, Tomkin GH. Cellular cholesterol regulation: a defect in the Type-2 (non-insulin dependent) diabetic patient in poor metabolic control. Diabetologia 33, 93-99 (1990). (Pubitemid 20060986)
13. Dimitriadis E, Griffin M, Owens D, Johnson A, Collins P, Tomkin GH. Oxidation of low density lipoprotein in non-insulin dependent diabetes: its relationship to fatty acid composition. Diabetologia 38, 1300-1306 (1995).
14. Bowie A, Owens D, Collins P, Johnson A, Tomkin GH. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient. Atherosclerosis 102, 63-67 (1993). (Pubitemid 23269731)
15. Younis N, Sharma R, Soran H, Charlton-Menys V, Elseweidy M, Durrington PN. Glycation as an atherogenic modification of LDL. Curr. Opin. Lipidol. 19, 378-384 (2008).
16. St Pierre AC, Cantin B, Dagenais GR et al. Low-density lipoprotein subfractions and the longterm risk of ischemic heart disease in men: 13-year follow-up data from the Quebec cardiovascular study. Arterioscler. Thromb. Vasc. Biol. 25, 553-559 (2005). (Pubitemid 40315677)
17. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I) trial. Am. J. Cardiol. 90(2), 89-94 (2002). (Pubitemid 34775113)
18. Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the stanford coronary risk intervention project. Circulation 94, 2146-2153 (1996). (Pubitemid 26360507)
19. Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 99, 1959-1964 (1999). (Pubitemid 29183891)
20. Manninen V, Tenkanen L, Koskinen P et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation 85, 37-45 (1992).
21. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and the treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation 92, 1779-1785 (1995).
22. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol: veterans affairs high-density lipoprotein cholesterol intervention trials study group. N. Engl. J. Med. 341, 410-418 (1999). (Pubitemid 29362514)
23. Keech A, Simes RJ, Barter P et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type-2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849-1861 (2005).
24. Shafrir E, Raz I. Diabetes: mellitus or lipidus? Diabetologia 46, 433-440 (2003).
25. Reaven GM. Banting lecture. Role of insulin resistance in human disease. Diabetes 37, 1595-1607 (1988). (Pubitemid 19004941)
26. Syvanne M, Taskinen MR. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 350 (Suppl. 1), SI20-SI23, (1997). (Pubitemid 27303533)
27. U.K. Prospective Diabetes Study 27. Plasma Lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 20, 1683-1687 (1997).
28. Friedlander Y, Kidron M, Caslake M, Lamb T, McConnell M, Bar-On H. Low density lipoprotein particle size and risk factors of insulin resistance syndrome. Atherosclerosis 148, 141-149 (2000).
29. Austin MA, Mykkanen L, Kuusisto J et al. Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 92, 1770-1778 (1995).
30. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J. Clin. Invest. 92, 141-146 (1993). (Pubitemid 23208989)
31. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler. Thromb. 12, 1496-1502 (1992).
32. Berneis K, Jeanneret C, Muser J, Felix B, Miserez AR. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in Type-2 diabetes. Metabolism 54, 227-234 (2005). (Pubitemid 40174852)
33. Chambless LE, Heiss G, Folsom AR et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am. J. Epidemiol. 146, 483-494 (1997). (Pubitemid 27391409)
34. Craven TE, Ryu JE, Espeland MA et al. Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case-control study. Circulation 82, 1230-1242 (1990).
35. Salonen JT, Salonen R. Ultrasound β-mode imaging in observational studies of atherosclerotic progression. Circulation 87, II56-II65 (1993). (Pubitemid 23068573)
36. Wofford JL, Kahl FR, Howard GR, McKinney WM, Toole JF, Crouse JR 3rd. Relation of extent of extracranial carotid artery atherosclerosis as measured by β-mode ultrasound to the extent of coronary atherosclerosis. Arterioscler. Thromb. 11, 1786-1794 (1991).
37. Goya K, Kitamura T, Inaba M et al. Risk factors for asymptomatic atherosclerosis in Japanese Type-2 diabetic patients without diabetic microvascular complications. Metabolism 52, 1302-1306 (2003). (Pubitemid 37351098)
38. Niskanen L, Rauramaa R, Miettinen H, Haffner SM, Mercuri M, Uusitupa M. Carotid artery intima-media thickness in elderly patients with NIDDM and in nondiabetic subjects. Stroke 27, 1986-1992, (1996). (Pubitemid 26372568)
39. Rizzo M, Rini GB, Berneis K. The clinical relevance of LDL size and subclasses modulation in patients with Type-2 diabetes. Exp. Clin. Endocrinol. Diabetes 115, 477-482 (2007). (Pubitemid 350056758)
40. Winkler K, Abletshauser C, Hoffmann MM et al. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with Type-2 diabetes mellitus: baseline LDL profile determines specific mode of action. J. Clin. Endocrinol. Metab. 87(12), 5485-5490 (2002). (Pubitemid 36034348)
41. Kazama H, Usui S, Okazaki M, Hosoi T, Ito H, Orimo H. Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in Type-2 diabetes. Diabetes Res. Clin. Pract. 59(3), 181-189 (2003). (Pubitemid 36183301)
42. Geiss HC, Schwandt P, Parhofer KG. Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipoproteinemia. Exp. Clin. Endocrinol. Diabetes 110(4), 182-187 (2002). (Pubitemid 34619630)
43. Freed MI, Ratner R, Marcovina SM et al. Rosiglitazone study 108 investigators. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in Type-2 diabetes mellitus. Am. J. Cardiol. 90(9), 947-952 (2002). (Pubitemid 35232617)
44. Pontrelli L, Parris W, Adeli K, Cheung RC. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/Type-2 diabetes. Metabolism 51(3), 334-342 (2002). (Pubitemid 34232636)
45. Wagner AM, Jorba O, Bonet R, Ordonez-Llanos J, Perez A. Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. J. Clin. Endocrinol. Metab. 88(7), 3212-3217 (2003). (Pubitemid 36877496)
46. Ikejiri A, Hirano T, Murayama S et al. Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients. Metabolism 53(9), 1113-1117 (2004). (Pubitemid 39140742)
47. Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in Type-2 diabetes mellitus with mixed hyperlipoproteinemia. Am. J. Cardiol.87(1), 44-48 (2001). (Pubitemid 32013083)
48. Geiss HC, Otto C, Schwandt P, Parhofer KG. Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects. Metabolism 50(8), 983-988 (2001). (Pubitemid 32755017)
49. Soedamah-Muthu SS, Colhoun HM, Thomason MJ et al. CARDS Investigators. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in Type-2 diabetic patients with ischaemic heart disease. Atherosclerosis 167, 243-255 (2003). (Pubitemid 36773524)
50. Lahdenpera S, Tilly-Kiesi M, Vuorinen-Markkola H, Kuusi T, Taskinen MR. Effects of gemfibrozil on low-density lipoprotein particle size, density distribution and composition in patients with type II diabetes. Diabetes Care 16, 584-592 (1993). (Pubitemid 23097206)
51. O'Neal DN, O'Brien RC, Timmins KL et al. Gemfibrozil treatment increases low-density lipoprotein particle size in Type-2 diabetes mellitus but does not alter in vitro oxidizability. Diabet. Med. 15, 870-877 (1998). (Pubitemid 28451958)
52. Kondo A, Morita H, Nakamura H et al. Influence of fibrate treatment on malondialdehyde-modified LDL concentration. Clin. Chim. Acta 339, 97-103 (2004). (Pubitemid 37542463)
53. Hayashi K, Kurushima H, Kuga Y et al. Comparison of the effect of bezafibrate on improvement of atherogenic lipoproteins in Japanese familial combined hyperlipidemic patients with or without impaired glucose tolerance. Cardiovasc. Drugs Ther. 12, 3-12 (1998). (Pubitemid 28190831)
54. Feher MD, Caslake M, Foxton J, Cox A, Packard CJ. Atherogenic lipoprotein phenotype in Type-2 diabetes: reversal with micronised fenofibrate. Diabetes Metab. Res. Rev. 15, 395-399 (1999). (Pubitemid 30066226)
55. Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution and hemorheologic parameters in Type-2 diabetes mellitus with mixed hyperlipoproteinemia. Am. J. Cardiol. 87, 44-48 (2001). (Pubitemid 32013083)
56. Tan CE, Chew LS, Tai ES et al. Benefits of micronised fenofibrate in Type-2 diabetes mellitus subjects with good glycemic control. Atherosclerosis 154, 469-474 (2001). (Pubitemid 32146621)
57. Vakkilainen J, Steiner G, Ansquer JC et al. DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).Circulation 107, 1733-1737 (2003). (Pubitemid 36418352)
58. Pan J, Lin M, Kesala RL, Van J, Charles MA. Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes. Diabetes Obes. Metab. 4, 255-261 (2002). (Pubitemid 34814866)
59. Pan J, Van JT, Chan E, Kesala RL, Lin M, Charles MA. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes. Metabolism 51, 1120-1127 (2002).
60. Patti L, Maffettone A, Iovine C et al. Long-term effects of fish oil on lipoprotein subfractions and low density lipoprotein size in non-insulin-dependent diabetic patients with hypertriglyceridemia. Atherosclerosis 146, 361-367 (1999). (Pubitemid 29418068)
61. Petersen M, Pedersen H, Major-Pedersen A, Jensen T, Marckmann P. Effect of fish oil versus corn oil supplementation on LDL and HDL subclasses in Type-2 diabetic patients. Diabetes Care 25, 1704-1708 (2002). (Pubitemid 41071074)
62. Mostad IL, Bjerve KS, Lydersen S, Grill V. Effects of marine n-3 fatty acid supplementation on lipoprotein subclasses measured by nuclear magnetic resonance in subjects with Type II diabetes. Eur. J. Clin. Nutr. 62(3), 419-429(2007) (Pubitemid 351356583)
63. Woodman RJ, Mori TA, Burke V et al. Docosahexaenoic acid but not eicosapentaenoic acid increases LDL particle size in treated hypertensive Type-2 diabetic patients. Diabetes Care 26, 253 (2003). (Pubitemid 36929035)
64. Farnier M, Freeman MW, Macdonell G et al. The Ezetimibe Study Group. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur. Heart J. 26, 897-905 (2005). (Pubitemid 40676570)
65. Hayashi T, Hirano T, Yamamoto T, Ito Y, Adachi M. Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with Type-2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies. Metabolism 55, 879-884 (2006). (Pubitemid 43902889)
66. Chu NV, Kong AP, Kim DD et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with Type-2 diabetes. Diabetes Care 25, 542-549 (2002). (Pubitemid 41103350)
67. Inoue I, Shinoda Y, Nakano T et al. Acarbose ameliorates atherogenecity of low-density lipoprotein in patients with impaired glucose tolerance. Metabolism 55, 946-952 (2006). (Pubitemid 43902898)
68. Winkler K, Friedrich I, Baumstark MW, Wieland H, Marz W. Pioglitazone reduces atherogenic dense low density lipoprotein (LDL) particles in patients with Type-2 diabetes mellitus. Br. J. Diabetes Vasc. Dis. 2, 1431-1448 (2002).
69. Perez A, Khan M, Johnson T, Karunaratne M. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with Type-2 diabetes. Diab. Vasc. Dis. Res. 1, 44-50 (2004).
70. Parhofer KG, Otto C, Geiss HC et al. Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus Type-2 - results of a pilot study. Exp. Clin. Endocrinol. Diabetes 113, 49-52 (2005). (Pubitemid 40321705)
71. Lautamaki R, Nuutila P, Airaksinen KE et al. The Effect of PPARg-Agonism on LDL subclass profile in patients with Type-2 diabetes and coronary artery disease. Rev. Diabet. Stud. 3, 31-38 (2006).
72. Yu D, Murdoch SJ, Parikh SJ et al. Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with Type-2 diabetes on statin therapy. Diab. Vasc. Dis. Res. 3, 189-196 (2006). (Pubitemid 44902486)
73. Albaladejo Otón MD, Calle Luna JG, Granero Fernández E, Hernández Martínez AM, Parra Pallarés S, Martínez Hernández P. [LDL concentration and particle size after treatment with rosiglitazone in patients with diabetes mellitus Type-2.] Med. Clin. (Barc.) 132, 98-101 (2009).
74. Rizzo M, Vekic J, Koulouris S et al. Effects of rosiglitazone on fasting and postprandial low-and high-density lipoproteins size and subclasses in Type-2 diabetes. Angiology 61, 584-590 (2010).
75. Rizzo M, Christ ER, Rini GB, Spinas GA, Berneis K. The differential effects of thiazolidindiones on atherogenic dyslipidemia in Type-2 diabetes: what is the clinical significance ? Expert Opin. Pharmacother. 9, 2295-2303 (2008).
76. Chappuis B, Braun M, Stettler C et al. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with Type-2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab. Res. Rev. 23, 392-399 (2007). (Pubitemid 47091243)
77. Deeg MA, Buse JB, Goldberg RB et al. On behalf of the GLAI study investigators. pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with Type-2 diabetes and dyslipidemia. Diabetes Care 30, 2458-2464 (2007). (Pubitemid 47547772)
78. Berneis K, Rizzo M, Stettler C et al. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type-2 diabetes. Expert Opin. Pharmacother. 9, 343-349 (2008). (Pubitemid 351291781)
79. Rizzo M, Rizvi AA, Spinas GA, Rini GB, Berneis K. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP4-inhibitors. Expert Opin. Inv. Drug 18, 1495-1503 (2009).
80. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in Type-2 Diabetes. N. Engl. J. Med. 358, 2545-2559 (2008).
81. Rizzo M, Berneis K, Zeljkovic A, Vekic J. Should we routinely measure low-density and high-density lipoprotein subclasses? Clin. Lab. 55, 421-429 (2009).
82. Mikhailidis DP, Elisaf MS, Rizzo M et al. 'European Panel on Low Density Lipoprotein (LDL) Subclasses': a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr. Vasc. Pharmacol. 9(5), 533-571 (2011).
83. Mikhailidis DP, Elisaf MS, Rizzo M et al. 'European Panel on Low Density Lipoprotein (LDL) Subclasses': a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr. Vasc. Pharmacol. 9(5), 531-532 (2011).
84. Rizzo M, Berneis K. The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates. Curr. Med. Res. Opin. 23, 1103-1111 (2007). (Pubitemid 46799594)
85. Rizzo M, Rini GB, Berneis K. Effects of statins, fibrates, rosuvastatin and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients. Adv. Ther. 24, 575-582 (2007). (Pubitemid 47295434)
86. Rizzo M, Berneis K. The clinical relevance of low-density-lipoproteins size modulation by statins. Cardiovasc. Drugs Ther. 20, 205-217 (2006). (Pubitemid 44121036)
87. Rizzo M, Berneis K, Spinas GA, Rini GB, Kapur NK. Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance ? Int. J. Clin. Pract. 63, 478-485 (2009).
88. Florentin M, Liberopoulos EN, Moutzouri E, Rizos CV, Tselepis AD, Elisaf MS. The effect of simvastatin alone vs. simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr. Med. Res. Opin. 27, 685-692 (2011).
89. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Ezetimibe and low density lipoprotein subfractions: an ongoing debate. Curr. Med. Res. Opin. 27, 693-695 (2011).
90. Rizzo M, Rini GB. Ezetimibe, cardiovascular risk and atherogenic dyslipidemia. Arch. Med. Sci. 7, 5-7 (2011).
91. Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W, Gouni-Berthold I. Ezetimibe alone or in combination with simvastatin increases small, dense low-density lipoproteins in healthy men: a randomized trial. Eur. Heart J. 31, 1633-1639 (2010).
92. Schwartz SL, Ratner RE, Kim DD et al. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with Type-2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. Clin. Ther. 30, 858-867 (2008). (Pubitemid 351799869)
93. DeFronzo RA, Okerson T, Viswanathan P, et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying and caloric intake: a randomized, cross-over study. Curr. Med. Res. Opin. 24, 2943-2952 (2008).
94. Matikainen N, Manttari S, Schweizer A et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with Type-2 diabetes. Diabetologia 49, 2049-2057 (2006). (Pubitemid 44168471)
95. Schwartz EA, Koska J, Mullin MP et al. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset Type-2 diabetes mellitus. Atherosclerosis 212, 217-222 (2010).
96. Bandsma RHJ, Lewis GF. Newly appreciated therapeutic effect of GLP-1 receptor agonists: reduction in postprandial lipemia. Atherosclerosis 212, 40-41 (2010).
97. Parlevliet ET, Schroder-van der Elst JP, Corssmit EP et al. CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat fed mice. J. Pharmacol. Exp. Ther. 328, 240-248 (2009).
98. Nakano T, Inoue I, Seo M et al. Rapid and simple profiling of lipoproteins by polyacrylamide-gel disc electrophoresis to determine the heterogeneity of low-density lipoproteins (LDLs) including small, dense LDL. Recent Pat. Cardiovasc. Drug Discov. 4, 31-36 (2009).
99. Inoue I, Awata T, Katayama S. Retrospective, observation study: quantitative and qualitative effect of ezetimibe and HMG-CoA reductase inhibitors on LDL-cholesterol: are there disappearance thresholds for small, dense LDL and IDL? Recent Pat. Cardiovasc. Drug Discov. 5, 143-152 (2010).
100. Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 83, 59-67 (1990). (Pubitemid 20210746)